Shares of Laboratory Corporation of America Holdings dropped more than 5 percent Monday after a report said the medical lab operator is in talks to acquire privately held contract researcher Pharmaceutical Product Development for more than $8 billion, including debt.
The North Carolina-based company’s deal would be its largest acquisition ever and would help its strategy of combining testing services under one roof, according to Reuters, citing people familiar with the matter.
